ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
23 avr. 2018 16h05 HE
|
ChromaDex Corporation
IRVINE, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, today announced a new...
TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
05 avr. 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it...
New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health
29 mars 2018 07h30 HE
|
ChromaDex Corporation
IRVINE, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that...
ChromaDex Corporation Reports 2017 Financial Results
08 mars 2018 16h01 HE
|
ChromaDex Corporation
IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today...
ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018
06 mars 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
ChromaDex Sets Fourth Quarter and Full Year 2017 Conference Call for Thursday, March 8, 2018 at 4:30 p.m. ET
02 mars 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
20 févr. 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today...
ChromaDex Chairman Stephen Allen Will Retire from Board of Directors
16 févr. 2018 16h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
ChromaDex Corporation Reports Preliminary 2017 Results
12 févr. 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way...
National Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s Disease
08 févr. 2018 06h30 HE
|
ChromaDex Corporation
IRVINE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the...